Clinical OMICs - Issue 3 - (Page 8)

Future Cancer Care: Anticipating "Panomics" with Bioinformatics Patricia Fitzpatrick Dimond, Ph.D. I n 2009 Mark Boguski and colleagues published a paper entitled "Customized care 2020: how medical sequencing and network biology will enable personalized medicine." In the paper the authors described a model incorporating these pathways, annotation of disease networks and drug targets, and simulation of therapeutic interventions with virtual drugs or with combinations of them. The pathology report of the future, the authors said, will provide precision diagnoses that are at the core of personalized medicine and will be an interactive software tool for clinical teams to design a customized care regimen and monitor its efficacy during treatment. Beyond cancer, noted Zhu et al. in their 2007 paper in PLOS Computational Biology, molecular dissection of diseases such as obesity and diabetes will require a systematic approach to show how genes interact with one another, and with genetic and environmental factors. With respect to cancer, completion of the human genome sequence has led to a postgenomic era that includes detailed exploration of the DNA sequence (the genome), DNA sequences that are transcribed into mRNA (the transcriptome), and the translated and post-translationally modified PATRICIA FITZPATRICK DIMOND, Ph.D. protein sequences (the proteome). The new paradigm in canhas been a long-time contributor to GEN cer, researchers say, encompasses analysis of entire gene and and currently serves as the publication's protein sets to identify a "reasonable" drug target. Multiple Technical Editor. She is also president of experimental and data analysis methodologies are being BioInsight Communications. During her career in the biotechnology industry, used to achieve this goal, and bioinformatics support is an she was VP of strategic development essential component of this research effort. and corporate communications at Coley As a discipline, according to Abeloff's Clinical Oncology, Pharmaceutical Group (now Pfizer), where she developed and managed the company's "bioinformatics sits at the interface where biology and mediinvestor relations and communications programs. cine meet a confluence of quantitative sciences, including ( computer science, mathematics, and statistics." While we are 8 Clinical OMICs May 15, 2014

Table of Contents for the Digital Edition of Clinical OMICs - Issue 3


Clinical OMICs - Issue 3